The global insulin active pharmaceutical ingredient market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). API is defined as any substance or combination of substances used in a finished pharmaceutical Product (FPP), intended to furnish pharmacological activity or  otherwise have direct impact on the diagnosis, mitigation, cure, treatment or prevention of disease, or have direct effect in restoring, correcting or modifying physiological functions in human being. The growing intervention of monoclonal antibodies, gene therapy products, virus vaccines, and other biological drug products in the field of healthcare are anticipated to drive the global insulin active pharmaceutical ingredient market. There are generally two types of active insulin active pharmaceutical ingredient available as chemical synthetics, and animal extracts. However, type 3 and type 4 are now considered to be the added types of active insulin active pharmaceutical ingredient.

Another key trend which is affecting the market growth includes the automatic substitution of these pharmaceutical ingredients. As per the National Center for Biotechnology Information (NCBI), in Germany the contracts between the joint organization of the health insurance companies and pharmacies state that the exchange between an originator product and a drug containing the API (biosimilar) is possible if the API in both cases stems from the same production facility (identical raw substances and production processes). However, this is not the case for any insulin formulation. Automatic substitution is not permitted in most European countries and other parts of the globe. Such regulations are likely to provide a major boost to the market growth during the forecast period.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape:  Novo Nordisk A/S, and Eli Lilly and Co., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Insulin Active Pharmaceutical Ingredient Market Report by Segment

By Type

• Chemical Synthetics

• Animal Extracts

By Application

• Animal Insulin

• Regular Human Insulin

• Insulin Analogue

Global Insulin Active Pharmaceutical Ingredient Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa